NOVO-NORDISK NAM.B DK-.20 news, videos and press releases
For more news please use our advanced search feature.
NOVO-NORDISK NAM.B DK-.20 - More news...
NOVO-NORDISK NAM.B DK-.20 - More news...
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk raises sales and operating profit outlook for 2023
- Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk conducts a two-for-one stock split
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk's sales increased by 29% in Danish kroner and by 30% at constant exchange rates to DKK 107.7 billion in the first six months of 2023
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
